CMP
RXRX icon

Coston McIsaac & Partners’s Recursion Pharmaceuticals RXRX Stock Holding History

Coston McIsaac & Partners’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-48
Closed – – 910
2026
Q1 		$0 Buy
+48
New +$185 ﹤0.01% 896
2024
Q4 		– Sell
-14
Closed – – 822
2024
Q3 		$0 Buy
+14
New +$100 ﹤0.01% 808

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Coston McIsaac & Partners's RXRX Position: Q2 2026 in Review

Coston McIsaac & Partners sold out of Recursion Pharmaceuticals (RXRX) in Q2 2026, closing a stake of 48 shares.

Coston McIsaac & Partners first reported a position in RXRX in Q3 2024 and held it in 2 quarters. The position peaked at $0 in Q1 2026. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Coston McIsaac & Partners reported no remaining Recursion Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Coston McIsaac & Partners sold 48 Recursion Pharmaceuticals shares in Q2 2026.
  • Coston McIsaac & Partners first reported a position in Recursion Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Coston McIsaac & Partners's Recursion Pharmaceuticals position peaked at $0 in Q1 2026.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Coston McIsaac & Partners's 13F filing for Q2 2026, filed 12 Aug 2026.